TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Finding the Optimum Regimen for Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of signed and dated informed consent form.~* Confirmed diagnosis of Duchenne muscular dystrophy~* Age greater than or equal to 4 years and less than 8 years old~* Ability to rise independently from floor, from supine to standing~* Willingness and ability to comply with scheduled visits, drug administration plan and study procedures~* Ability to maintain reproducible FVC measurements.~Exclusion Criteria:~* History of major renal or hepatic impairment, immunosuppression or other contraindications to corticosteroid therapy.~* History of chronic systemic fungal or viral infections. Acute bacterial infection(including TB) would exclude from enrolment until the infection had been appropriately treated and resolved.~* Diabetes mellitus.~* Idiopathic hypercalcuria.~* Lack of chicken pox immunity and refusal to undergo immunization.~* Evidence of symptomatic cardiomyopathy at screening assessment (one to three months prior to the baseline visit). Asymptomatic cardiac abnormality on investigation would not be an exclusion.~* Current or previous treatment (greater than four consecutive weeks of oral therapy) with corticosteroids or other immunosuppressive treatments for DMD or other recurrent indications (e.g., asthma), unless approved by FOR-DMD Team (i.e., concurrent participation in another allowed DMD trial).~* Inability to take tablets, as assessed by the site investigator by the end of the screening period (the screening period ranges from one to three months prior to the baseline visit).~* Allergy/sensitivity to study drugs or their formulations including lactose and/or sucrose intolerance.~* Severe behavioral problems, including severe autism.~* Previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow up will be correctly completed or impair the assessment of study results, in the judgment of the site investigator.~* Weight of less than 13 kilograms.~* Exposure to any investigational drug currently or within 3 months prior to start of study treatment.

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Daily prednisone (Type: EXPERIMENTAL): daily prednisone (0.75 mg/kg/day)
- Intermittent prednisone (Type: EXPERIMENTAL): intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off)
- Daily deflazacort (Type: EXPERIMENTAL): daily deflazacort (0.9 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Peritoneal Carcinomatosis With PIPAC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Histological or cytological verified malignancy.~* Clinical or radiological evidence of peritoneal carcinomatosis.~* No indication for standard chemotherapy.~* Performance status 0-2 and life expectancy of more than 3 months.~* Age \> 18 years.~* Written informed consent must be obtained according to the local Ethics Committee requirements.~Exclusion criteria~* Symptomatic small bowel obstruction (Total parenteral nutrition, nasogastric tube).~* Previous treatment with maximum cumulative doses of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones.~* A history of allergic reaction to cisplatin or other platinum containing compounds or doxorubicin.~* Renal impairment, defined as GFR \< 50 ml/min, (Cockcroft-Gault Equation).~* Myocardial insufficiency, defined as NYHA class \> 2.~* Impaired liver function defined as bilirubin ≥ 1,5 x UNL (upper normal limit).~* Inadequate haematological function defined as ANC ≤ 1.5 x 109/l and platelets ≤ 100 x 109/l.~* Any other condition or therapy, which in the investigator's opinion may pose a risk to the patient or interfere with the study objectives.~* Previous intraabdominal chemotherapy or intraabdominal antibody therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PIPAC (Type: EXPERIMENTAL): PIPAC with cisplatin (7.5mg/m2 in 150 ml saline) and doxorubicin (1.5mg/m2 in 50 ml saline) in patients with peritoneal metastases (PM) from any origin besides colorectal/appendiceal cancers in whom oxaliplatin (92mg/m2 in 150 ml dextrose) will be used.~The aerosolised chemotherapy will be nebulized at a flow of 0.5ml/min at a maximum pressure of 200 PSI during a standard laparoscopy with an intraabdominal pressure of 12mmHg. The CO2 will be evacuated 30 minutes after administration of chemotherapy and the patient is closed similar to a standard laparoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Smoke-Break Liquid Cigarettes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Volunteer is at least 18 years of age.~* Volunteer currently smokes cigarettes, cigars or other forms of tobacco products for at least one year.~* Volunteer wants to quit smoking.~* Volunteer will be fully informed as to the nature of the study.~* Volunteer will have no known allergy to any product ingredients as listed in the informed consent.~* Volunteer agrees to a confidential pretest questionnaire and periodic monitoring as to the effectiveness of the smoking cessation regimen.~* Volunteers are not currently using another nicotine replacement therapy.~* Volunteer will agree to use birth control measures while on the study.~Exclusion Criteria:~* Volunteer has a known allergy or hypersensitivity to nicotine or other related ingredients as outlined in the informed consent.~* Volunteer does not desire to quit smoking.~* Volunteer is using another nicotine replacement therapy.~* Volunteer is pregnant or breast-feeding.~* Volunteer has a history of heart disease or advanced diabetes.~* Volunteer indicates on the application that they smoke ten (10) or fewer cigarettes per day.~* Volunteer is using a daily prescription medicine for depression or asthma.~* Volunteer is using a non-nicotine smoke cessation drug, such as Zyban or Chantix.~* Volunteer is an employee of Smoke-Break Inc., or is personally known to an employee of Smoke-Break Inc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active Smokers (Type: EXPERIMENTAL): Active smokers who used the Smoke-Break nicotine delivery device in an attempt to quit smoking cigarettes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Patients must be receiving hemodialysis; have elevated parathyroid hormone levels; not be pregnant or nursing; and not have had a heart attack in the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG 073 (Type: EXPERIMENTAL): AMG 073
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of XP12B in Women With Menorrhagia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women with menorrhagia~* 18-49 years of age~* Regularly occurring menstrual periods~Exclusion Criteria:~* History or presence of clinically significant disease or abnormalities that may confound the study~* History of bilateral oophorectomy or hysterectomy~* Hormone therapy for birth control

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for at least 3 months~* HbA1c between 7.5-11.0% on monotherapy or~* HbA1c between 7.0-10.0% on dual therapy~* BMI maximum 45 kg/m2~Exclusion Criteria:~* Any clinically significant disease history in the opinion of the investigator~* Severe heart disease~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years with informed consent~* Diagnosed with rheumatoid arthritis as determined by meeting the 2010 ACR/EULAR classification criteria and has had rheumatoid arthritis for at least 6 weeks~* Swollen joint (SJC)≥3 and tender joint count(TJC)≥5~* ESR \>28 mm/hr or C-reactive protein \> 20 mg/L~Exclusion Criteria:~* Pregnant, lactating or further fertility requirements~* Previous treated with methotrexate or biologic DMARD.~* Active or chronic infection, including HIV, HCV, HBV, tuberculosis~* Patient with cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Methotrexate (Type: PLACEBO_COMPARATOR): Patients were treated with methotrexate alone.
- T2 (Type: EXPERIMENTAL): Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
- MTX+T2 (Type: EXPERIMENTAL): The patients were treated with methotrexate and T2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Asian Female patients at least 18 years of age~* Clinical or surgical diagnosis of endometriosis (depending on local approved indication) : Clinical diagnosis by suggestive symptoms and positive finding in imaging study (Chocolate cyst)~* Patients with Endometriosis associated pelvic pain~* Decision taken by the physician to newly prescribe Visanne®~* Availability of a signed informed consent~Exclusion Criteria:~* Patients participating in an investigational program with interventions outside of routine clinical practice~* Patients for whom any of contraindication listed in the local summary of product characteristics (SPC) apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: None): Asian patients at least 18 years of age with clinical or surgical diagnosis of endometriosis, and patients with endometriosis associated pelvic pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cochlear Implantation in Adults With Asymmetric Hearing Loss Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* English as the native language~* Have a desire for functional binaural hearing~* Have failed a previous hearing aid (HA) treatment for asymmetric hearing loss (BiCROS or poor ear HA) or willing to complete a trial if necessary~* Willingness to comply with all study requirements~* Ability to provide informed consent~* Poor ear (ear to be implanted):~  * Pure-tone average (PTA) at .5, 1 and 2 kilohertz (kHz) \> 70 dB HL (hereafter referred to as severe to profound hearing loss - SPHL)~ * Aided word recognition score (CNC Word Test) at 60 dB SPL ≤ 30%~ * Duration of SPHL ≥ 6 months~ * Onset of hearing loss ≥ 6 years of age~* Better ear:~  * PTA at .5, 1, 2, 4 kHz of 40 to 70 dB HL~ * Currently using a HA~ * Aided word recognition score (CNC Word Test) at 60 dB SPL \> 40%~ * Stable hearing for the previous 1-year period. Stable is defined as thresholds that have not changed by more than 10 dB at 2 or more octave interval audiometric frequencies~Exclusion Criteria:~* Medical condition that contraindicates surgery~* Actively using an implantable device in the ear to be implanted~* Known cochlear malformation or obstruction that would preclude full insertion of the electrode array in the ear to be implanted~* Hearing loss of neural or central origin~* Unrealistic expectations related to the benefits and limitations of cochlear implantation~* Unwillingness or inability to comply with all investigational requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cochlear Implantation (Type: EXPERIMENTAL): Cochlear implantation of the poor hearing ear

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Prucalopride to Treat Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and non-pregnant, non breast-feeding female outpatients at least 18 years of age (no upper age limit).~2. History of constipation; the subject reports, on average, two or fewer spontaneous bowel movements per week that result in a feeling of complete evacuation and one or more of the following for at least 6 months before the selection visit:~   1. very hard (little balls) and/or hard stools at least a quarter of the stools~  2. sensation of incomplete evacuation following at least a quarter of the stools~  3. straining at defecation at least a quarter of the time. The above criteria are only applicable for spontaneous bowel movements, i.e., not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.~Subjects who never have spontaneous bowel movements are considered to be constipated and are eligible for the trial.~Exclusion Criteria:~1. Subjects in whom constipation is thought to be drug-induced, or subjects using any disallowed medication.~2. Subjects suffering from endocrine disorders, metabolic disorders or neurologic disorders.~3. Subjects with a megacolon/megarectum or a diagnosis of pseudo-obstruction.~4. Constipation as a result of surgery.~5. Known or suspected organic disorders of the large bowel, i.e. obstruction, carcinoma, or inflammatory bowel disease.~6. Subjects with severe and clinically uncontrolled cardiovascular, liver, or lung disease, neurologic or psychiatric disorders (including active alcohol or drug abuse), cancer or AIDS, and other gastrointestinal or endocrine disorders.~7. Subjects with impaired renal function.~8. Subjects with clinically significant abnormalities of haematology, urinalysis, or blood chemistry.~9. Females of child-bearing potential without adequate contraceptive protection during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Prucalopride 2 mg
- 3 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: ACTIVE_COMPARATOR): Prucalopride 4 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion criteria:~* Histologically documented marginal zone lymphoma including splenic, nodal, and extranodal sub-types; subjects with splenic MZL must have an additional measurable lesion, nodal or extranodal, as described in inclusion criteria 5~* Previously received one or more lines of therapy including at least one CD20-directed regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to achieve at least PR or documented PD after, the most recent systemic treatment regimen~* Men and women ≥18 years of age~* ECOG performance status of ≤2~* ≥1 measurable lesion site on CT scan (\>1.5 cm in longest dimension). Lesions in anatomical locations (such as extremities or soft tissue lesions) that are not well visualized by CT may be measured by MRI instead. (Subjects with spleen-only disease are considered as not having measurable disease.)~* Life expectancy of \>3 months, in the opinion of the investigator~Key Exclusion criteria:~* Medically apparent CNS lymphoma or leptomeningeal disease~* History of other malignancies except adequately treated non melanoma skin cancer, curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for ≥2 years~* History of allogeneic stem-cell (or other organ) transplantation~* Any chemotherapy, anticancer antibodies, or other systemic anticancer therapy within 21 days of the first dose of study drug~* Any external beam radiation therapy within 6 weeks prior to the first dose of the study drug~* Concurrent use of warfarin or other vitamin K antagonists~* Concurrent use of a strong CYP3A inhibitor. Subjects who have received a strong CYP3A inhibitor prior to entering the study must have discontinued therapy for at least 5 half lives of the prohibited medication.~* Recent infection requiring IV anti-infective treatment that was completed ≤14 days before the first dose of study drug~* Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to CTCAE Grade 0 or 1, or to the levels dictated in the eligibility criteria with the exception of alopecia~* Inadequate organ function as defined on laboratory tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ibrutinib (Type: EXPERIMENTAL): ibrutinib capsules: 560 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to give written informed consent~2. Confirmed MS diagnosis as defined by the McDonald criteria~3. R-R MS disease course.~4. At least one gadolinium-enhanced lesion on screening MRI~5. Women of child-bearing potential must practice a reliable method of birth control.~6. Must understand the requirements of the study and agree to comply with the study protocol.~Exclusion Criteria:~1. Subjects who suffer from any form of progressive MS.~2. Any condition which the investigator feels may interfere with participation in the study.~3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation,~4. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening~5. Previous treatment with immunomodulators within two months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Laquinimod 0.3 mg (Type: ACTIVE_COMPARATOR): Laquinimod 0.3 mg
- Laquinimod 0.6 mg (Type: ACTIVE_COMPARATOR): Laquinimod 0.6 mg
- Placebo (Type: PLACEBO_COMPARATOR): Blinded Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete